Anything that helps Americans lose weight, reduces treatment barriers and makes care more affordable should be welcomed. But let's not fool ourselves.
A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at ...
About VIVUS VIVUS is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical ...
Participants in the combined treatment group lost significantly more weight at 3, 6, and 12 months and were more likely to lose 5%, 10%, or >15% of their body weight at 12 months compared with DELI al ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results